Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-year Effect and Safety of Semaglutide 2.4 mg in Adults with Overweight or Obesity
NCT03693430Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2018
- Primary completion
- Jan 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
A Phase 3 trial of semaglutide in obesity, Overweight, sponsored by Novo Nordisk. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03693430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693430.